Search results for "Marr"

showing 10 items of 776 documents

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct

Sister chromatid exchange in Waldenström's macroglobulinemia

1993

Results on sister chromatid exchange (SCE) frequency and interchromosomal distribution in bone marrow and peripheral blood cultures from patients with Waldenström's macroglobulinemia are reported. PHA-stimulated bone marrow cultures showed increased SCE frequencies in all 12 patients examined. The increase was particularly high in two cases (17.07 and 16.77 SCE/cell, respectively) and, in one of them, a very high SCE level was found in PHA-stimulated peripheral blood culture (40.81 SCE/cell). In LPS-stimulated cultures, increased SCE levels were observed in some patients. Comparison between SCE frequency in bone marrow cell cultures with either mitogen showed a significant increase in PHA-s…

AdultMaleCancer ResearchG chromosomeCellSister chromatid exchangeBiologyGeneticsmedicineHumansPooled dataMolecular BiologyAgedCell CycleMacroglobulinemiaWaldenstrom macroglobulinemiaMiddle AgedCell cyclemedicine.diseaseMolecular biologySettore BIO/18 - Geneticamedicine.anatomical_structureImmunologySister chromatid exchanges Waldenstrom's macroglobulinemiaFemaleBone marrowWaldenstrom MacroglobulinemiaSister Chromatid ExchangeCancer Genetics and Cytogenetics
researchProduct

Pneumonia in Febrile Neutropenic Patients and in Bone Marrow and Blood Stem-Cell Transplant Recipients: Use of High-Resolution Computed Tomography

1999

PURPOSE: To obtain statistical data on the use of high-resolution computed tomography (HRCT) for early detection of pneumonia in febrile neutropenic patients with unknown focus of infection. MATERIALS AND METHODS: One hundred eighty-eight HRCT studies were performed prospectively in 112 neutropenic patients with fever of unknown origin persisting for more than 48 hours despite empiric antibiotic treatment. Fifty-four of these studies were performed in transplant recipients. All patients had normal chest roentgenograms. If pneumonia was detected by HRCT, guided bronchoalveolar lavage was recommended. Evidence of pneumonia on chest roentgenograms during follow-up and micro-organisms detected…

AdultMaleCancer ResearchHigh-resolution computed tomographymedicine.medical_specialtyNeutropeniamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaFever of Unknown OriginPredictive Value of TestsmedicineHumansProspective StudiesFever of unknown originLungAgedBone Marrow TransplantationAged 80 and overmedicine.diagnostic_testbusiness.industryRespiratory diseaseHematopoietic Stem Cell TransplantationPneumoniaMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesSurgeryLeukemia Myeloid AcutePneumoniaBronchoalveolar lavageOncologyFemaleRadiologyTomography X-Ray ComputedComplicationbusinessBronchoalveolar Lavage FluidAlgorithmsJournal of Clinical Oncology
researchProduct

Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.

2006

We reviewed a large series of patients with essential thrombocythemia diagnosed on the basis of the Polycythemia Vera Study Group criteria, and reclassified them by evaluating their major morphologic features and clinical course using the World Health Organization classification. The morphologic review of the bone marrow biopsies of 116 patients (44 males and 72 females; aged 19 - 83 years, median 55 years; median follow-up 121 months) led to 22 cases (19%) being classified as essential thrombocythemia (ET), 24 (21%) as chronic idiopathic myelofibrosis (CIMF)-0, 44 (37%) as CIMF-1, 13 (12%) as CIMF-2, 9 (8%) as latent phase polycythemia vera, and four (3%) as chronic myeloproliferative diso…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyIdiopathic myelofibrosisSingle CenterWorld healthDiagnosis DifferentialPolycythemia veraBone Marrowhemic and lymphatic diseasesmedicineHumansPolycythemia VeraAgedAged 80 and overEssential thrombocythemiabusiness.industryHistologyBone Marrow ExaminationHematologyMiddle Agedmedicine.diseaseHaematopoiesismedicine.anatomical_structureOncologyPrimary MyelofibrosisChronic DiseaseFemaleBone marrowbusinessGranulocytesThrombocythemia EssentialLeukemialymphoma
researchProduct

Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes.

2001

BACKGROUND Splenic marginal zone cell lymphoma (SMZL) is a low grade B-cell lymphoma in which patients can have circulating villous lymphocytes and can show a peculiar intrasinusoidal bone marrow (BM) infiltration. Splenectomy is the reported treatment of choice for these patients. The objective of this study was to evaluate the effects of splenectomy on patients with BM lymphomatous infiltration. METHODS BM biopsies of 16 patients with SMZL were studied morphologically and immunohistochemically. In 12 patients, BM biopsies were taken before and after splenectomy. Four patients did not undergo splenectomy, and their BM biopsies were performed with an approximately 1 year interval. RESULTS B…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentSplenectomySpleenLymphocytosisBone MarrowmedicineHumansIn patientSplenic marginal zone lymphomaAgedbusiness.industryLymphoma Non-HodgkinSplenic lymphoma with villous lymphocytesMiddle Agedmedicine.diseaseLymphomamedicine.anatomical_structureOncologySplenectomyFemaleBone marrowbusinessInfiltration (medical)Cancer
researchProduct

Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement

2005

Abstract Splenic Marginal Zone Lymphoma (SMZL), with or without villous lymphocytes (VL+/-), is a low-grade lymphoproliferative disorder with constant involvement of the bone marrow (BM). Different BM infiltration patterns, mainly intra-sinusoidal, interstitial and nodular, have been described. Adhesion molecules (AMs) constitute a heterogeneous group of antigenic receptors playing a major role in leukocyte recruitment, in lymphocyte homing and in cellular-mediated immune response. Evolution and pattern of the BM infiltrate could be influenced by a variable expression of AM on SMZL lymphocytes. The degree and pattern of BM infiltration and the immunohistochemical expression of AM (H-CAM, BL…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphomasplenic marginal zone lymphomaBiologyImmunophenotypingAntigenAntigens NeoplasmBone MarrowmedicineHumansLymphocytesSplenic marginal zone lymphomabone marrow involvementLymphocyte homing receptorAgedCell adhesion moleculeSplenic NeoplasmsHematologyMiddle Agedrole of adhesion moleculemedicine.diseaseImmunophenotypic profilemedicine.anatomical_structureOncologyReticular connective tissueImmunohistochemistryFemaleBone marrowCell Adhesion MoleculesInfiltration (medical)
researchProduct

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical-pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found i…

AdultMaleCancer Researchmedicine.medical_specialtyLymphomaAnemiamedicine.medical_treatmentSplenectomysplenic marginal zone lymphomaGastroenterologyBone marrow biopsyIntrasinusoidalInternal medicinemedicineHumansLymphocytesLeukocytosisSplenic marginal zone lymphomaSurvival rateAgedAged 80 and overLeukopeniabusiness.industrySplenic Neoplasmssplenic marginal zone lymphoma; PrognosisSplenic lymphoma with villous lymphocytesMiddle AgedPrognosismedicine.diseaseSplenic NeoplasmSurgerySurvival Ratemedicine.anatomical_structureOncologySplenectomySplenic lymphoma with villous lymphocyteLymphocyteFemaleBone marrowmedicine.symptombusinessHumanCancer
researchProduct

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor.

1989

The in vivo effect of yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) was investigated in 30 patients with advanced malignancy in a phase Ib trial. Patients were treated at four different dose levels (120 to 1,000 micrograms/m2/d) by either daily intravenous (IV) bolus injection or 24-hour continuous infusion. Administration of rh GM-CSF resulted in a broad spectrum of dose- and schedule-dependent hematopoietic effects. Sustained infusion of rh GM-CSF elicited a maximum 17-fold average peak increase of the total WBC count with mainly neutrophils, eosinophils, and monocytes accounting for this rise, and increases in bone marrow cellularity with a…

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentMicrogramMalignancyDrug Administration ScheduleLeukocyte CountColony-Stimulating FactorsIn vivoBone MarrowInternal medicineNeoplasmsmedicineHumansPlateletLeukocytosisGrowth SubstancesInfusions IntravenousAgedbusiness.industryPlatelet CountGranulocyte-Macrophage Colony-Stimulating FactorMiddle Agedmedicine.diseaseRecombinant ProteinsHematopoiesisHaematopoiesisEndocrinologyGranulocyte macrophage colony-stimulating factormedicine.anatomical_structureOncologyImmunologyInjections IntravenousDrug EvaluationFemalemedicine.symptombusinessmedicine.drugJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct